Pharmaceuticals, Biotechnology and Life Sciences
Thermo Fisher Scientific and Servier’s affiliate Symphogen have announced the continuation of their collaboration to provide biopharmaceutical discovery and development…
Pharma companies didn’t want to comment effects of the sanctions against Russia.
PARIS–(BUSINESS WIRE)–Servier and its partner Taiho Pharmaceutical Co., Ltd announced today that the European Commission (EC) has approved the use…
Treatment emergent adverse events Grade 3 or higher were reported by 20 of 32 patients from the 50/60 dose pooled patient analysis; no patient reported Grade 3 or higher fatigue or peripheral neuropathy (primary endpoint) –
Servier and Galapagos NV have started a global Phase 2 trial with S201086/GLPG1972 in knee osteoarthritis patients, titled Roccella, in…
GeNeuro’s results from the Phase 2b study of its novel therapeutic treatment of multiple sclerosis (MS) showed a significant, consistent positive…
GeNeuro and Servier on Monday said that GNbAC1, for the treatment of certain multiple sclerosis was well tolerated, without statistical…
Servier and CTI BioPharma Corp. will expand their agreement regarding Pixuvri, which will give Servier rights to sell it anywhere but…
Servier has been cleared with Investiga New Drug (IND) by the U.S. Food and Drug Administration (FDA) for the clinical development of UCART19, an allogeneic, gene-edited cellular therapy candidate to treat relapsed/refractory acute lymphoblastic leukemia.
Horizon Discovery Group plc, the international life science company supplying research tools and services that power genomics research and the development of personalised medicines, has announced that its leveraged business unit has signed a programme in-licensing and option agreement with Servier, the independent French research-based pharmaceutical company .